String Bio achieved the Generally Recognized as Safe (GRAS) status of its innovative microbial protein, PRO-DG™, for use in crustacean feed in the U.S. This landmark achievement was affirmed by an independent panel of experts who rigorously evaluated the body of published data supporting the safety of PRO-DG™ for its intended use.

The GRAS status, governed by the US Food and Drug Administration (FDA), sets a high standard for ingredients to be approved for use in both feed and food. String Bio’s PRO-DG™ stands out as it contains approximately 70% protein derived from methanotrophic bacteria, manufactured through the company’s patented String Integrated Methane Platform (SIMP®). This advanced platform ensures an ideal amino acid profile, resulting in high digestibility and performance, as validated in various aqua trials. Notably, the protein's tolerability by shrimp was evidenced through peer-reviewed publications (Felix et al., 2023; Nederlof et al., 2023).

Achieving GRAS status, which took over two years of comprehensive scientific documentation and safety studies, distinguishes String Bio from other players in the alternative protein industry.

“The FDA-regulated GRAS status will enable the commercialization of PRO-DG™ in the United States, opening new markets and opportunities for growth. Many countries look to GRAS status as a strong indication that a feed ingredient has been rigorously tested to meet the highest standard. GRAS status of PRO-DG™ is an important milestone in String’s journey and will boost String Bio’s market presence in the feed sector,” said Ezhil Subbian, CEO, String Bio.